Search Results - therapeuticarea+%3e+immunology

194 Results Sort By:
Next-Generation 5-HT-2B Serotonin-Receptor Antagonists for Anti-Fibrotic & Cardiopulmonary Therapy
This technology includes a family of small-molecule antagonists that selectively block the 5-HT2B serotonin receptor—an upstream driver of tissue-remodeling—to address fibrotic, cardiopulmonary and related disorders. Built on a conformationally-locked “(N)-methanocarba” nucleoside scaffold, the compounds show nanomolar potency,...
Published: 5/14/2025   |   Inventor(s): Kenneth Jacobson, Dilip Tosh
Keywords(s):  
Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Cardiology, TherapeuticArea > Dermatology, TherapeuticArea > Immunology, TherapeuticArea > Metabolic Disease, TherapeuticArea > Oncology, TherapeuticArea > Pulmonology, TherapeuticArea > Respiratory
Nanobody–Antiviral Peptide Conjugates for Potent HIV Entry Inhibition
This technology includes a new class of nanobody–antiviral peptide conjugates that block HIV from infecting human CD4⁺ T-cells, positioning them for future therapeutic and prophylactic use. Nanobodies—single-domain antibody fragments—guide the drug to the virus’s docking site and impede receptor binding, while the linked peptide...
Published: 5/14/2025   |   Inventor(s): Ross Cheloha, Shubhra Saha
Keywords(s):  
Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease, TherapeuticArea > Reproductive Health
Broadly neutralizing influenza hemagglutinin stem-directed antibodies
In 2023, the World Health Organization (WHO) reported roughly 3 to 5 million cases of severe influenza worldwide, resulting in approximately 290,000 to 650,000 deaths. Given the high disease burden, the needs for both prophylactic and therapeutic influenza strategies remain significant. However, current treatments for influenza are susceptible to resistance...
Published: 5/8/2025   |   Inventor(s): Sarah Andrews, Grace Mantus, Ankita Chopde, Adrian Creanga, Rebecca Gillespie, Masaru Kanekiyo, Julie Raab
Keywords(s):  
Category(s): Application, Application > Therapeutics, Application > Vaccines, Collaboration Sought, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Collaboration Sought > Materials Available, ResearchProducts > Antibodies, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology
A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions
The Plasmodium parasite has a complex lifecycle during human infection and in the mosquito vector. Most advanced malaria vaccine candidates can confer only partial, short-term protection in malaria-endemic areas. A means of breaking the transmission of malaria to subsequent individuals could prevent a significant amount of human disease. The primary...
Published: 5/8/2025   |   Inventor(s): Patrick Duffy, Jonathan Renn
Keywords(s):  
Category(s): Application, Application > Research Materials, Application > Therapeutics, Application > Vaccines, Collaboration Sought, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts > Sequences, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease
Francisella Lipids as Broad Anti-inflammatory Therapeutics
Anti-inflammatory treatments, particularly those used in the context of viral infection, have been shown to greatly inhibit the overall immune response, which can result in poor immunity and failure to control or clear the infection. Novel alternatives that can effectively attenuate inflammation without the more serious side effects of steroid medications...
Published: 5/13/2025   |   Inventor(s): Catharine Bosio, Glenn Nardone, Robin Ireland
Keywords(s):  
Category(s): Application, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, TherapeuticArea > Immunology
Fluorinated MU-Opioid Receptor Agonists
Summary: Investigators at the National Institute on Drug Abuse seek co-development partners and/or licensees for collection of mu opioid receptor (MOR) agonists as alternatives for existing compounds. Description of Technology: Although existing opioids are excellent analgesics and useful as positron emission tomography (PET) radiotracers, they come...
Published: 4/22/2025   |   Inventor(s): Michael Michaelides, Juan Gomez, Kenner Rice, Agnieszka Sulima, Michael Baumann
Keywords(s):  
Category(s): Application, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Immunology, TherapeuticArea > Neurology, TherapeuticArea > Radiology, Collaboration Sought > Licensing
A Fundamental Tool for Efficient Recovery of RNA Viruses through Reverse Genetics
BSR T7/5 cells represent a foundational advancement in virology, offering a robust platform for the recovery of RNA viruses via reverse genetics. Established over 20 years ago, these cells have proven instrumental in the recovery of a wide array of RNA viruses, particularly those belonging to the mononegavirales order. By enabling the insertion of antigenome...
Published: 12/10/2024   |   Inventor(s): Ursula Buchholz
Keywords(s):  
Category(s): Application > Therapeutics, Application > Vaccines, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Research Equipment, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease
Bispecific Antibody Targeting Anthrax Toxins and Capsule for Enhanced Biodefense
The technology focuses on the development of a tetravalent bispecific antibody effective against Bacillus anthracis, the bacterium responsible for anthrax. This antibody combines the specificities of two monoclonal antibodies (mAbs): one targeting anthrax protective antigen (PA) and the other targeting the bacterial capsule. The anti-PA mAb shows potent...
Published: 12/10/2024   |   Inventor(s): Zhao Chun Chen, Robert Purcell, Mahtab Moayeri, Stephen Leppla
Keywords(s):  
Category(s): Application > Therapeutics, Application > Vaccines, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Antibodies, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease
Transgenic Mouse Models for Studying HLA-B57:01 and HLA-B15:02 Linked Immune Responses and Hypersensitivity Reactions
Transgenic mouse models expressing human HLA-B57:01 and HLA-B15:02 molecules have emerged as invaluable tools for unraveling the intricacies of immune responses and hypersensitivity reactions. The major histocompatibility complex (MHC) encoded proteins play a pivotal role in the immune system by presenting peptide fragments to T lymphocytes, and HLA-B57:01...
Published: 12/10/2024   |   Inventor(s): David Margulies, Kannan Natarajan, Mulualem Tilahun, Michael Norcross, Lisa Boyd
Keywords(s):  
Category(s): Application > Research Materials, Collaboration Sought > Collaboration, ResearchProducts > Animal Models, ResearchProducts > Research Equipment, TherapeuticArea > Immunology
Characterization and Comparison of LAD2 and LADR Mast Cell Lines: Insights into Mastocytosis and HIV Infection
LAD2 and LADR cell lines are invaluable tools in mast cell research, offering insights into mastocytosis and immune responses. Derived from CD34+ cells, LAD2 cells have been extensively used for over 18 years, while LADR cells, a newer variant, exhibit enhanced characteristics such as larger size, increased granulation, and faster doubling time. Both...
Published: 12/10/2024   |   Inventor(s): Arnold Kirshenbaum, Dean Metcalfe
Keywords(s):  
Category(s): Application > Research Materials, Collaboration Sought > Collaboration, ResearchProducts > Human Cell Lines, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease
1 2 3 4 5 6 7 8 9 10 ...